Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report discusses a 5-year-old boy with alopecia totalis who initially experienced regrowth after treatment with Prosential, minoxidil 2%, and clobetasol propionate 0.05%, but later relapsed.

In this study, microneedling combined with bleomycin treatment for plantar warts improved the response time and reduced the number of treatment sessions needed, with a relapse rate similar to other injection-based methods.

This study found that the proprietary aptamer TAGX-0003 significantly inhibited IFNγ-induced effects in pre-clinical human models of alopecia areata, promoting hair regrowth and potentially preventing disease relapse.

This case report describes a 43-year-old male patient with alopecia totalis successfully regaining all his hair after six months of treatment with tofacitinib, with no relapse observed after one year.

This case report describes a 43-year-old male with alopecia totalis who successfully regrew all his hair after six months of treatment with tofacitinib, with no relapse at one year.

In this study, eight Chinese patients with alopecia areata showed hair regrowth following combination therapy with a nonablative laser and topical minoxidil, with most patients not experiencing relapse after one year, suggesting a promising alternative treatment without significant side effects.

This study reported that topical calcipotriol led to complete scalp hair regrowth in three patients with alopecia totalis, with no relapse observed for 6 months post-treatment.

This study found that high skin expression of amphiregulin in acute graft-versus-host disease was associated with severe disease grade, poor overall survival, and increased non-relapse mortality.

This study found that both ruxolitinib and tofacitinib were effective in promoting hair regrowth for patients with severe alopecia areata, with no significant difference in efficacy and relapse rate between them, and both were well tolerated throughout the treatment.

This case report describes a 12-year-old boy who developed severe shingles with skin erosion and hair loss despite early aciclovir treatment after a stem-cell transplant for relapsed acute myeloid leukemia.

The document concludes that low-dose acne treatment is most suitable for moderate acne, with high patient satisfaction and low relapse rates.

This case report describes a Brittany spaniel that developed erythema multiforme possibly linked to cephalexin and then pemphigus foliaceus, which improved with prednisolone without relapse for four years.

This source highlights that alopecia areata is a complex autoimmune disorder leading to patchy, nonscarring hair loss with variable treatment responses, reflecting unmet clinical needs. Advances in genetic research are improving understanding, yet current treatments often lead to persistent relapses.

In this case report, upadacitinib was used to treat a 21-year-old female with severe alopecia areata, resulting in significant hair regrowth; however, rapid hair loss recurred soon after discontinuing the drug, illustrating its potential efficacy as well as the risk of relapse upon stopping treatment.

Hair loss can occur as a side effect of certain breast cancer treatments, but minoxidil can help regrow hair.

This case report describes a 69-year-old woman who developed drug-induced acquired ichthyosis related to ponatinib therapy, which improved upon stopping the medication.

This case report describes a 21-year-old woman with circumscribed alopecia areata incognita, who experienced a sustained positive response to treatment with oral tofacitinib after conventional treatments frequently failed to provide lasting effects.

This case report documented a 74-year-old female with alopecic patches and other skin issues during talquetamab therapy for multiple myeloma, suggesting that the drug may cause skin-related adverse effects due to reactivity to GPRC5D-expressing structures.

Using Selenium Disulfide shampoo weekly helps prevent scalp dermatitis flare-ups.

This study introduces a novel in vitro model for clubfoot fibrosis to enable high-throughput drug screening and found that while the model increased collagen deposition, the antifibrotic drug minoxidil effectively inhibited the expression of collagen cross-linking enzymes.

This study reported that IL-15 promotes human hair growth and protects hair follicle immune privilege, potentially stabilizing alopecia areata treatment outcomes when selectively stimulating IL-15Rα signaling.

This study presents a case where telemedicine allowed for early detection of a dermatomyositis flare during the COVID-19 pandemic using simple patient-reported measures, despite challenges in remote assessment.

This review discusses current treatment options for liver hydatidosis, noting the potential benefits and limitations of chemotherapy and highlighting the need for more clinical trials to prevent recurrent disease; it reports no new findings.

This review discusses evidence for alopecia areata treatments, highlighting their ability to stimulate hair growth but noting limited data on long-term efficacy and impact on quality of life.

In this study, rituximab treatment for children with steroid-dependent nephrotic syndrome was associated with a longer remission time and fewer side effects compared to cyclophosphamide.

Hair follicles in the nose may need better cleaning to prevent Staphylococcus aureus infections.

This study identified multiple factors affecting the severity of alopecia areata, suggesting they could inform a tool for measuring disease impact and guide treatment selection.

This study found that teriflunomide, an oral medication taken once daily, significantly slowed disability progression in patients with relapsing multiple sclerosis, supported by positive results in two Phase III trials and supplemented by various analyses including long-term studies and patient-reported outcomes.

This case report describes a 31-year-old woman experiencing alopecia areata as a potential side effect of alemtuzumab treatment for relapsing-remitting MS.

This study shows that in a mouse model of Alopecia Areata, selective JAK1 inhibition facilitated hair regrowth and inflammation resolution while potentially offering a better safety profile compared to pan-JAK inhibition.